Skip to main content
Clinical Trials/NCT01787448
NCT01787448
Completed
Phase 1

Repeat-insult Patch Test (Ript) of Ibuprofen 5% Topical Gel in Human Volunteers

Pfizer1 site in 1 country234 target enrollmentStarted: January 2013Last updated:

Overview

Phase
Phase 1
Status
Completed
Sponsor
Pfizer
Enrollment
234
Locations
1
Primary Endpoint
Dermal sensitization potential

Overview

Brief Summary

This study is being conducted to determine the potential of Ibuprofen 5% Topical Gel and its vehicle gel to cause sensitization after repeated topical application to healthy skin of human subjects under controlled conditions.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy male or female subjects 18 years of age or older, female subjects of childbearing potential and males are using an acceptable form of birth control, subjects are free of any systemic or dermatologic disorder

Exclusion Criteria

  • Have any visible skin disease at the application site, not willing to stop use of systemic or topical analgesics, corticosteroids, or antihistamines, not willing to stop use of sunscreens, creams, or similar products on the back during the study

Arms & Interventions

Ibuprofen 5% topical gel

Experimental

Intervention: Topical gel vehicle (Drug)

Topical gel vehicle

Experimental

Intervention: Topical gel vehicle (Drug)

Sodium lauryl sulfate 0.1%

Active Comparator

Intervention: Sodium lauryl sulfate 0.1% (Drug)

Sodium chloride solution 0.9% (saline)

Sham Comparator

Intervention: Sodium chloride solution 0.9% (saline) (Drug)

Outcomes

Primary Outcomes

Dermal sensitization potential

Time Frame: 24-72 hours after last patch removal

Secondary Outcomes

  • Cumulative Irritancy(48-72 hours after each patch application)
  • Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)(During study through 28 days after last product application)

Investigators

Sponsor
Pfizer
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials